Medical Uses
FARESTON (toremifene) is a hormone tablet for metastatic breast cancer in women who have gone through menopause. The US label covers tumours that are oestrogen-receptor positive or whose receptor status is unknown. The European licence describes it as first-line hormone treatment for hormone-dependent metastatic disease and says it is not recommended when the tumour is oestrogen-receptor negative.
Toremifene belongs to the same triphenylethylene family as tamoxifen. It sits on the oestrogen receptor in place of oestradiol, so the hormone can no longer push the tumour cells to copy their DNA and divide. The label notes that it can act partly like oestrogen in some tissues, which explains several of its side effects. It is broken down mainly by the liver enzyme CYP3A4 and has a long half-life of about 5 days, so a steady level builds up only after 4 to 6 weeks.
Three randomised trials compared 60 mg toremifene with tamoxifen in about 1,150 postmenopausal women. In the North American study the response rate was 21.3% with toremifene against 19.1% with tamoxifen, and median survival was 33.6 versus 34.0 months. The Eastern European study gave similar results; in the Nordic study time to progression was longer with tamoxifen (10.2 versus 7.3 months). Higher doses of 200–240 mg worked no better than 60 mg.
For a wider picture of hormone-positive disease, see our guide to advanced HR-positive, HER2-negative breast cancer. Newer oral options we also source include Orserdu (elacestrant) and Truqap (capivasertib).
